SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights

DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the

IVVD

Related stories